Natco recall a case to bolster drug controlPitfalls in the Indian drug regulations came to light last week when it was reported that a newly launched anti-cancer drug was asked to be withdrawn by the Drug Controller General of India.
July 23, 2009
Daiichi fails to gain much from Ranbaxy buyoutsThose acquisitions do not look as exciting now as they were made out to be.
July 21, 2009
‘Efficacy’ point in Glivec ruling impracticalToo many contentious issues in IPAB’s patent rejection to the Novartis drug.
July 11, 2009
Biotechnology can be the next big driver for the pharma sectorThe coming together of Biocon and Mylan for a biogenerics entry coincided with a study done by EvaluatePharma.
July 3, 2009
Give research its due; help only the deservingPharma companies working on genuine leads seldom seek government support.
June 27, 2009
Proprietary lines, biosimilars hold the next level for Dr Reddy’sAfter reaching the $1.5 billion mark in revenues, growth is easier said than secured.
June 4, 2009
With Malvinder out, inevitable has come to pass at RanbaxyIt was a matter of time before Daiichi took full control — that time’s come.
May 26, 2009
US aggression on pharma patents bodes ill for the worldThe Indian pharmaceutical industry has faced tremendous pressure from world bodies on issues like counterfeit drugs.
May 21, 2009
India needs its Hatch-Waxman Act for healthcareThe Hatch-Waxman Act, a legislation that transformed the American drug industry, completed 25 years last week.
May 15, 2009
Swine flu vaccine will take at least a yearMounting toll due to swine flu is keeping governments and health agencies on their toes across the world as scientists are trying to understand the deadly strain.
April 30, 2009
Archrivals join hands for AIDS fightIn an unprecedented show of solidarity, archrivals GSK and Pfizer have come together to form a new company ideally created to tackle the pandemic of AIDS.
April 24, 2009
Jail-term clause will help cleanse clinical trialsBreach of clinical trial norms could invite ten years in jail, under the new guidelines being framed by the government.
April 17, 2009
Hard to believe an exciting player like Wockhardt is ailingAs with any other ambitious Indian company, Wockhardt chairman Habil Khorakiwala wanted to grow by tapping opportunities in the emerging generic markets.
April 9, 2009
|
ReportsOur columnists
Contributors
|
|
||||||